Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3134]

ASH 2015: New vaccine strategy better protects high-risk cancer patients from flu

ASH 2015: New vaccine strategy better protects high-risk cancer patients from flu

$ASH 2015: Results from phase 2 study for treatment of relapsed or refractory hodgkin lymphoma following autologous stem cell transplantation$

ASH 2015: Results from phase 2 study for treatment of relapsed or refractory hodgkin lymphoma following autologous...

ASH 2015: First targeted therapy for genetically defined subset of patients with acute myeloid leukaemia significantly improves survival

ASH 2015: First targeted therapy for genetically defined subset of patients with acute myeloid leukaemia...

ASH 2015: Study finds new use for rituximab in acute leukaemia

ASH 2015: Study finds new use for rituximab in acute leukaemia

ASH 2015: Ixazomib for relapsed and treatment-resistant multiple myeloma

ASH 2015: Ixazomib for relapsed and treatment-resistant multiple myeloma

ASH 2015: First targeted therapy for multiple myeloma effective against hard-to-treat disease

ASH 2015: First targeted therapy for multiple myeloma effective against hard-to-treat disease

ASH 2015: Study underscores promise of targeted therapies as first-line approach for patients with chronic lymphocytic leukaemia

ASH 2015: Study underscores promise of targeted therapies as first-line approach for patients with chronic...

ASH 2015: Combination therapy with idelalisib better prevents disease progression in relapsed or treatment-resistant chronic lymphocytic leukaemia than current regimen

ASH 2015: Combination therapy with idelalisib better prevents disease progression in relapsed or treatment...

ASH 2015: Experimental oral therapy for ultra high-risk chronic lymphocytic leukaemia shows promise

ASH 2015: Experimental oral therapy for ultra high-risk chronic lymphocytic leukaemia shows promise

ASH 2015: Study suggests warfarin is acceptable for long-term treatment of cancer-associated thrombosis

ASH 2015: Study suggests warfarin is acceptable for long-term treatment of cancer-associated thrombosis

More from ecancer